Kornimate/medical-research-clean huggingface dataset:
pulmonary embolism in pregnancy: biomarkers and clinical predictive models

Conditions: Pulmonary Embolism

Summary: objective: to evaluate whether trimester specific d-dimer levels and brain natriuretic protein (bnp), along with the modified wells score (mws), is a useful risk stratification tool to exclude pregnant women at low-risk of pulmonary embolism (pe) from diagnostic imaging with radiation exposure.

to account for all women meeting the study eligibility criteria, this study utilized a combined prospective and retrospective arm. pregnant women who underwent diagnostic imaging to evaluate for suspected pe at our institution were prospectively enrolled from february 2014 to august 2015. both d-dimer and bnp serum levels were drawn, and a mws was assigned. all pregnant women diagnosed with a pe that underwent diagnostic imaging and had a d-dimer level drawn from january 2009 to june 2014 were retrospectively enrolled. patient electronic records were used to apply the mws and analyze their risk.

Eligibility criteria:
inclusion criteria: * adult pregnant women \>= 18 years old * d-dimer obtained and if the patient was pregnant at the time of pe diagnosis * patient presented to the emergency department or labor and delivery unit * patient presented with signs and symptoms suspicious for pe exclusion criteria: * non-pregnant patients * patients \< 18 years old

Keywords: pulmonary embolism pregnancy d-dimer
clearup longitudinal pilot study

Conditions: Sinus Pain; Congestion

Summary: single arm, open label pilot study assessing the longitudinal home use of clearup sinus pain relief for four weeks.


Eligibility criteria:
inclusion criteria: * 18-71 years of age (inclusive) * present with symptoms of sinus pain or facial pain in the forehead, periorbital, facial, or nasal region * current pain score ≥ 5 (numeric rating scale 0-10) * frequency of sinus/facial pain at least twice weekly for 1 month * able to read and understand english * agree to participate in the study * able and willing to provide informed consent exclusion criteria: * do not meet inclusion criteria * currently taking or recently taken any oral steroid medications in the last 90 days * sinus surgery in previous 90 days * history of chronic migraine (≥ 15 headache days per month) * pain location in the vertex, occiput, or temporal region of the skull or in mandibular region * purulent rhinorrhea
efficacy study of acupuncture to treat the upper abdominal pain of cancer patients

Conditions: Abdominal Pain

Summary: this study is to investigate the effectiveness of acupuncture for alleviating the upper abdominal pain of cancer patients

neurolytic celiac plexus block (ncpb) is a commonly performed procedure in patients with intractable pain due to malignancies involving the upper and mid abdomen. recently, acupuncture is used as one of alternative interventions to treat cancer-related pains. this pilot study aims to investigate the effectiveness of pain-relief of acupuncture via comparing acupuncture plus ncpb with ncpb alone. total 14 cancer patients with ncpb will be randomized into two groups of acupuncture and control.

Eligibility criteria:
inclusion criteria: * age over 18 years * upper abdominal pain vas ≥ 5 * unresectable abdominal malignancy, moderate or severe abdominal pain poorly controlled with pharmacotherapy. * all patients had advanced cancer diagnosed by histological/cytological examination * follow-up possible during the clinical trial * written informed consent voluntarily exclusion criteria: * patient with uncorrectable coagulopathy * patient with allergy to local anesthesics or alcohol.. * previous ncpb or had implanted epidural or intrathecal analgesic therapy * inability to lie prone * disease encasing the celiac plexus on computed tomography scan * patients with psychiatric diseases that could have affected the study assessments * significant renal or hepatic disease * inability to comprehend or express oneself in the korean language * refusal to participate in the trial or to provide informed consent
study assessing deep molecular response in adult patients with cml in chronic phase treated with nilotinib firstline.

Conditions: Chronic Myeloid Leukemia

Summary: the main purpose of this study was to evaluate the rate of deep molecular response (mr4.5) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase chronic myeloid leukemia (cml) using eutos (european treatment and outcome study for cml)-standardized laboratories. all participants received nilotinib 300 mg twice daily (bid).

this was a phase iv open-label, multi-center, single-arm study in participants with newly diagnosed philadelphia chromosome positive (ph+) cml in chronic phase for who nilotinib is the appropriate treatment at the discretion of the investigator. a screening period of 2 weeks was used to assess eligibility and to taper participants off disallowed medications. participants whose eligibility was confirmed entered a 24 months treatment phase with nilotinib 300mg bid. nilotinib was prescribed by the investigator according to the individual needs of the participants.

Eligibility criteria:
key inclusion criteria: * patients with newly diagnosed (within 6 months) philadelphia chromosome positive cml in chronic phase * patients must be previously untreated for cml with the exception of 6 months treatment with hydroxyurea and a maximum of 6 weeks treatment with imatinib * adequate end organ function * normal serum levels ≥ lower limit of normal (lln) of potassium, magnesium, total calcium corrected for serum albumin or phosphorus, or correctable to within normal limits with supplements, prior to the first dose of study medication. key exclusion criteria: * known impaired cardiac function like long qt syndrome, history of myocardial infarction or unstable angina in the past 12 months. * patients who are pregnant or breast feeding. other inclusion/exclusion criteria might apply

Keywords: chronic myeloid leukemia nilotinib molecular response mr4.5
single trans-sacral screw versus two iliosacral screws

Conditions: Pelvic Fracture

Summary: 1. to compare single trans-sacral screw fixation vs. two ilio-sacral screws fixation as regard time for starting weight bearing. 2. to compare between functional outcome using the majeed pelvic score.

sacroiliac screws (siss) have been used since vidal et al introduced them in 1973. since that, sis fixation has become a common technology in fixing pelvic posterior ring injuries with important progress in the past 20 years. currently, sis fixation represents the only minimally invasive technique to stabilize the posterior pelvic ring. for that reason, it is steadily gaining popularity, becoming one of the most commonly used techniques. the sacrum, serving as the foundation of the spine, transmits the stress between spine and pelvis through sacroiliac joints. thus, the goal of surgical fixation is the reconstruction of the spino-pelvic-junction to allow early weight-bearing and to facilitate nursing care, particularly for multiple injured patients. as a result of the deforming forces acting perpendicular to the implant axis, routine ilio-sacral screws fixation may not provide adequate stabilization, especially in certain unstable injuries. longer trans-sacral screws that traverse the entire upper sacrum and exit the contralateral iliac cortex may improve holding power and also stabilize concomitant contralateral posterior pelvic injuries. these trans-sacral screws are reliably safe to insert using routine intraoperative fluoroscopy, and they provide durable fixation.

Eligibility criteria:
inclusion criteria: 1. unstable pelvic fractures tile type b \& c. 2. sacral fractures. 3. recent trauma: less than 1 week from date of trauma. 4. neurologically free. 5. injury severity score (iss) \< 18. exclusion criteria: 1. spino-pelvic dissociation. 2. comminuted fractures 3. bilat. sacral fractures. 4. sacral insufficiency. 5. patients with associated comorbidities "eg. uncontrolled diabetes mellitus , chronic renal failure, etc.".
bupivacaine versus lidocaine on inflammatory regulation

Conditions: Pain

Summary: this study is testing a local anesthetic (numbing medicine) to suppress pain. bupivacaine and lidocaine are fda approved local anesthetics that may decrease pain following surgery. patients will receive either 2% lidocaine, 0.5% bupivacaine, or placebo with epinephrine 1:200,000 as a numbing medicine at the end of root canal surgery. small pieces of gum will be taken before and after surgery and 2 days later to analyze chemicals that may be related to pain sensation.

we hypothesize that the use of the lla bupivacaine will promote local inflammation leading to increased pain and central sensitization as evaluated by increase in pain at later time points. hence our main hypothesis to be evaluated and statistically tested for our primary endpoint (aim 1) is: ho: there is no difference in mean levels of biochemical mediators of inflammation between groups. ha: the bupivacaine group has higher levels of biochemical mediators following surgery.

Eligibility criteria:
inclusion criteria: * male or female volunteers referred for endodontic surgery willing to undergo 2 visits: 1 surgical appointment, and 1 follow-up research-related appointment * ages of 18 and older * willing to undergo observation for 1/2 hour post-operatively * willing to complete a 100 mm visual analog scale and record analgesic intake over 48 hrs period * willing to have a preoperative and postoperative biopsy on the day of surgery * willing to return at 48 hours post-operation to turn in completed pain diaries and for the third biopsy exclusion criteria: * allergy to or other contraindications to use of aspirin, sulfites, amide anesthetics, or acetaminophen * chronic use of medications confounding the assessment of the inflammatory response or analgesia, for example, nsaids, cox-2 inhibitors, antihistamines, steroids, antidepressants * medications contraindicated with bupivacaine: mao inhibitors and anti-depressants * diseases such as diabetes mellitus, liver disease, chronic infections, rheumatoid arthritis or any other systemic disease that compromises the immune system * unusual surgical difficulty

Keywords: bupivacaine inflammation pain local anesthetic peripheral sensitization
outpatient use of ivermectin in covid-19

Conditions: Covid19

Summary: covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people, can lead to severe disease in a significant portion. currently, it is expected that the majority, 81%, of patients with covid-19 will have mild to moderate disease, with 14% having more severe disease (2). there exists a number of candidate drugs that may inhibit sars-cov-2 infection or progression of disease. simple, safe and low-cost strategies that may be the best solution to inhibit infection and limit transmission and spread of infection. ivermectin is a drug initially synthesized and used as an anthelmintic. it has been found to have activity against several rna viruses such as the sars-cov-2 by mechanisms that inhibit importin α/β-mediated nuclear transport that may prevent viral proteins from entering the nucleus to alter host cell function. a recent in vitro study showed that a single dose of ivermectin could kill covid-19 in vitro within 48 hours. a recent multi-continent retrospective study of 1,400 patients demonstrated an association of ivermectin use with lower in-hospital mortality 1.4% versus 8.5%. given these findings and its safety profile, cost and ease of administration, ivermectin warrants study as a potential treatment to prevent progression of covid 19 infection.


Eligibility criteria:
inclusion criteria: 1. symptoms highly suspicious for covid-19. 2. age at least 18 years 3. negative pregnancy test for women of child bearing age 4. able to consent to participate in the study. exclusion criteria: 1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia identified by chest x-ray or high resolution ct scan 4. fever or cough present for more than 7 days 5. positive igg against sars-cov-2 by rapid test if available on baseline screening. 6. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: 1. immunosuppression 2. hiv 3. acute or chronic renal failure 4. current neoplasm 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. 8. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

Keywords: ivermectin covid
effect of retro-walking on postpartum low back pain

Conditions: Postpartum Disorder; Low Back Pain

Summary: this study will be conducted to determine the effect of retro walking on post partum low back pain.

postpartum lbp is a common musculoskeletal disorder. it occurs due to ligament laxity and postural changes that started during pregnancy or within 3 weeks of childbirth and continue for 3 months after delivery. when all forms of non-specific lbp were considered, approximately 33% of postpartum women had some lbp within 3 months after childbirth, and approximately 40% described moderate to severe disability. postpartum lbp stresses the sacroiliac joints and lumbosacral spine. previous studies of swedish women with postpartum lbp reported impairments to their daily activities with a prevalence ranging between 20-90%, but they seldom sought health care assistance or treatment. many researchers and clinicians have suggested that an increase in core strength and improvement in pelvic alignment are keys to resolve or avoid lbp. during backward walking, the typical heel-strike associated with ground contact is eliminated because the toe contacts the ground first and the pelvis is anteriorly aligned. this may open up the facet joints in the vertebral column and help in alleviating the pressure on intervertebral discs and the associated lbp. previous studies investigated the effect of retro walking on other types of lbp (non-specific and chronic) but till now, there is no previous study investigate the effect of retro walking on postpartum lbp related to c.s delivery. so, this study will be the first one in this issue. therefore, this study will be of valuable benefits for medical service organization and increase the body of knowledge in physical therapy field.

Eligibility criteria:
inclusion criteria: * multi parous women suffering from postpartum low back pain after cesarean delivery (from 6 weeks to 6 months after delivery). * their ages will range from 25-35 years old. * their body mass index will be less than 30 kg/m2. * they should have mild to moderate low back pain as scored on vas (represented by cut points on the scale recommending mild pain (5- 44mm), moderate pain (45- 74mm)) exclusion criteria: * recent surgeries, trauma or fractures of the lower limb or in the back region. * morbid cardiovascular disease. * liver or kidney dysfunction. * any neurological disorders including balance issues or motor and sensory loss. * any musculoskeletal disorders such as disc prolapsed, lumbar canal stenosis and spondylysthesis or severe knee osteoarthritis. * taking intra-articular injection for knee for the last 6 months. * those having visual dysfunction or refractory errors not corrected with glasses or contact lenses.
a retrospective cohort study about surgical efficacy for lower cervical fractures in ankylosing spondylitis

Conditions: Ankylosing Spondylitis (AS); Spine Fracture

Summary: the purpose of this retrospective cohort study was to observe and compare the efficacy of anterior cervical long segment fixation, posterior long segment fixation, and combined anterior and posterior fixation for the treatment of cervical vertebral fracture-dislocations in the lower cervical spine in ankylosing spondylitis.

this was a retrospective cohort study. patients operated for fracture-dislocation of the lower cervical vertebrae in ankylosing spondylitis in our hospital from 01/2014 to 01/2024 were retrospectively included as study subjects. prior to the start of the study, an application will be made for approval through the hospital ethical committee, and the declaration of helsinki will be observed during the course of the study. the patients were divided into an anterior group (anterior long-segment cervical fixation), a posterior group (posterior long-segment cervical fixation), and a combined group (combined anterior and posterior fixation) according to the surgical access. the operation time, bleeding, complication occurrence, fracture healing and changes in neurological function of the three groups were compared. in this study, frankel grading before and after surgery was used as the primary observation index, and operation time, intraoperative bleeding, occurrence of complications, and cervical fracture healing were used as the secondary observation index. spss 26.0 (ibm, new york, ny, usa) was applied for statistical analysis in this study.

Eligibility criteria:
inclusion criteria: meet the diagnostic criteria for ankylosing spondylitis, imaging showed that cervical ankylosing and fracture dislocation of the lower cervical vertebrae (cervical 3\~7); age 18\~80 years old; undergo anterior, posterior or combined access internal fixation surgery and the fixation segment is ≥4 segments. exclusion criteria: systemic or local infection; previous history of cervical vertebrae surgery; postoperative loss of follow-up.

Keywords: ankylosing spondylitis cervical fracture and dislocation anterior internal fixation and fusion posterior internal fixation and fusion
training of the inspiratory musculature in the improvement of inspiratory strength and muscle recovery in soccer players

Conditions: Breathing

Summary: soccer requires the activation of aerobic and anaerobic metabolism. the increase of the ventilatory demand stimulates the increase of the neural impulse to the respiratory muscles, increasing the mechanical power of the inspiratory muscles. the main objective of the study is to assess the effectiveness in the improvement of the strength of the inspiratory muscles and the muscular recovery with the powerbreathe® device in semi-professional soccer players. randomized double-blind clinical study with follow-up period. 36 semi-professional soccer players from the province of soria will be randomly distributed to the study groups: experimental (inspiratory muscle training with 50% resistance) and control (10% resistance training). the dependent variables will be: aerobic and anaerobic sports performance (cooper's 12-minute run test and repeated sprint ability), blood lactate concentration (lactate scout®), and lung function using the ergo-respiratory parameters (maximum inspiratory pressure, expiratory pressure maximum, forced vital capacity and forced expiratory volume in 1 second). the sample distribution will be calculated using the kolmogorov-smirnov test. the changes after each evaluation will be analyzed with the t-student test and with an anova of repeated measures, the intra and intersubject effect will be observed. the effect size will be calculated using cohen's formula. it is intended to observe improvement in inspiratory strength levels, decrease in blood lactate concentration and an increase in aerobic and anaerobic sports performance.


Eligibility criteria:
inclusion criteria: * football players * male * with an age range of 18 to 35 years * which currently compete in the category of spanish third division nationally. exclusion criteria: * subjects who have some type of injury that prevents them from practicing sports at the time of study * with medical diagnosis of respiratory pathology * that are not able to overcome the respiratory resistance of the device * have not signed the informed consent document.

Keywords: breathing exercises soccer maximal respiratory pressures muscle strength muscle fatigue
nosocomial covid-19 infections in patients hospitalized at the metz-thionville regional hospital in 2021

Conditions: SARS CoV 2 Infection

Summary: the rate of nosocomial sars-cov2 infections found in the different studies since the beginning of the pandemic is very variable (\<1% in hospitals in the usa to about 20% in a british hospital). mortality related to these nosocomial sars-cov2 infections is higher than in the general population. the risk factors identified for this nosocomial acquisition are multiple. we were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement. the objectives of this study are to determine the proportion of nosocomial sars cov 2 infections in the total number of patients hospitalized with a covid-19 infection at the chr metz-thionville in 2021, and to describe the characteristics of this population.


Eligibility criteria:
inclusion criteria: * patients hospitalised at the chr metz-thionville in medicine, surgery and obstetrics (mco) or geriatric follow-up and rehabilitation care (ssr) units, in 2021 for a covid-19 infection defined by the existence of a positive pcr result for sars-cov2 during the stay, or by the existence of an icd10 code for covid in the pmsi data of the health care establishment exclusion criteria: * opposition to participate in the study after reading the patient information note.
opioid package prototype (opp)

Conditions: Opioid Use; Opioid Prescribing, Dispensing, and Patient Use

Summary: the overall objective of this clinical trial is to identify the impact of selected package features, known as the opioid package prototype (opp), on the safe and effective use of opioids. our specific aims are: (aim 1) to evaluate the effectiveness of opp on prescribing, dispensing, and patient use of oxycodone among orthopaedic surgery patients receiving post-operative outpatient oxycodone for post-surgical pain management, and (aim 2) to determine the feasibility of opp for orthopaedic surgery prescribers, pharmacists, and orthopaedic surgery patients. such data can be used to further optimize packaging and labeling design, help patients and caregivers utilize their medication and packaging correctly, and improve prescribing and dispensing habits. the central hypothesis is that the opp will be more effective than the amber vial in efforts to reduce oxycodone prescribing among patients over 18 receiving short-term management of post orthopedic surgery pain.


Eligibility criteria:
inclusion criteria: 1. the patient is 18 years and older; 2. the patient is one of the participating surgeons; 3. the patient is receiving orthopaedic surgery that involves the use of opioid medication for post-operative pain; 4. the patient is willing to receive oxycodone medication; 5. the patient is willing and able to receive medication at the uconn health specialty pharmacy, located in the exchange across the street from the main entrance of uconn health; 6. the patient is willing and able to use a mychart account; 7. the patient is able to read and understand english; and 8. the patient is able to understand the study procedures and their involvement in the study. exclusion criteria: -

Keywords: oxycodone opioid opioids package packaging post-surgical pain post-operative pain orthopedic orthopaedic surgery dispensing prescribing blister tablets pain opioid package prototype opp